Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis - Summary - MDSpire
Advertisement
Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis
To assess the efficacy and safety of current and emerging treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents.
Key Findings:
MASLD prevalence is 7.6% in the general pediatric population and 34.2% in obesity clinics, highlighting the urgent need for effective interventions.
Key risk factors include obesity, type 2 diabetes, and sedentary lifestyles, emphasizing the importance of addressing these issues.
Lifestyle modifications remain the cornerstone of management, but adherence is challenging, necessitating additional support.
Pharmacologic options like vitamin E, metformin, and orlistat show promise but lack universal acceptance, indicating a gap in treatment guidelines.
Interpretation:
The findings highlight the critical need for effective pharmacological treatments for MASLD in pediatric populations, as current options are limited and adherence to lifestyle changes is often poor, underscoring the importance of further research.
Limitations:
Limited number of RCTs available for comprehensive analysis, which may affect the robustness of conclusions.
Variability in treatment protocols and outcomes measured across studies, which complicates the comparison of results.
Conclusion:
Further research is essential to develop targeted pharmacological interventions for pediatric MASLD to prevent progression to more severe liver disease.
